Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715)

What Was Tested

Researchers studied L-Carnitine in this randomized controlled trial publication.

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and disabling side effect of taxanes.

The researchers investigated the long-term patterns of CIPN among patients in this trial.

Who Took Part

According to the abstract, 24 women were involved.

PubMed indexes the participants as adults and middle-aged adults, women only.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

The women were allocated by chance, so the L-Carnitine group and the comparison group should start out alike.

Blinding on both sides kept the women and researchers unaware of who received L-Carnitine.

Some women received a placebo instead of L-Carnitine, giving a reference point.

More than one site took part, so the women came from several places.

The methods mention a period of two years.

CIPN was measured by the 11-item neurotoxicity (NTX) component of the FACT-Taxane scale at weeks 12, 24, 36, 52, and 104.

The researchers examined NTX scores over two years using linear mixed models for longitudinal data.

Individual time points were examined using linear regression.

Regression analyses included stratification factors and the baseline score as covariates.

All statistical tests were two-sided.

What Was Measured

The subject headings attached to it are Acetylcarnitine, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Chemotherapy, Adjuvant, Dietary Supplements, Docetaxel and Neurotoxicity Syndromes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of L-Carnitine in 24 women over two years.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Journal of the National Cancer Institute), a journal based in United States.

More context: the L-Carnitine compound page, all human trials.